Alzheimer disease: Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy

Gabriela Stoppe, Harald Bruhn, Petra J.W. Pouwels, Wolfgang Hänicke, Jens Frahm

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In vivo magnetic resonance spectroscopy of brain metabolites such as N-acetylaspartate and myo-inositol has been proposed for the diagnosis of Alzheimer disease. Thirty patients with probable Alzheimer disease as well as 22 elderly controls underwent quantitative proton magnetic resonance spectroscopy of parietal gray and white matter with use of a short-echo time localization technique (echo time, 20 ms; repetition times, 6000 and 3000 ms, 2.0 Tesla) providing access to the regional concentrations of N-acetylaspartate, creatine, choline-containing compounds, myo-inositol, glutamate, glutamine, and lactate. No statistically significant alterations of the metabolites were found in patients relative to controls. There were also no differences between patients with early and late onset of the disease and with respect to the presence of APOE-ε4 phenotype. A general trend for slightly decreased levels of N-acetylaspartate and creatine was not observed for their respective concentration ratios. In summary, the spectroscopic findings were in accord with known Alzheimer disease neuropathology, i.e., mild gliosis in white matter as well as mildly enhanced cortical atrophy in comparison to elderly controls. However, cortical atrophy with little or no N-acetylaspartate changes provided no evidence for a major decrease of neuronal density or loss of viable neurons. The data do not support the utility of proton magnetic resonance spectroscopy as an early diagnostic tool for Alzheimer disease.

Original languageEnglish
Pages (from-to)112-119
Number of pages8
JournalAlzheimer Disease and Associated Disorders
Volume14
Issue number2
DOIs
Publication statusPublished - 1 Apr 2000
Externally publishedYes

Cite this

@article{a856d352a99446a5a99de75be4f2e069,
title = "Alzheimer disease: Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy",
abstract = "In vivo magnetic resonance spectroscopy of brain metabolites such as N-acetylaspartate and myo-inositol has been proposed for the diagnosis of Alzheimer disease. Thirty patients with probable Alzheimer disease as well as 22 elderly controls underwent quantitative proton magnetic resonance spectroscopy of parietal gray and white matter with use of a short-echo time localization technique (echo time, 20 ms; repetition times, 6000 and 3000 ms, 2.0 Tesla) providing access to the regional concentrations of N-acetylaspartate, creatine, choline-containing compounds, myo-inositol, glutamate, glutamine, and lactate. No statistically significant alterations of the metabolites were found in patients relative to controls. There were also no differences between patients with early and late onset of the disease and with respect to the presence of APOE-ε4 phenotype. A general trend for slightly decreased levels of N-acetylaspartate and creatine was not observed for their respective concentration ratios. In summary, the spectroscopic findings were in accord with known Alzheimer disease neuropathology, i.e., mild gliosis in white matter as well as mildly enhanced cortical atrophy in comparison to elderly controls. However, cortical atrophy with little or no N-acetylaspartate changes provided no evidence for a major decrease of neuronal density or loss of viable neurons. The data do not support the utility of proton magnetic resonance spectroscopy as an early diagnostic tool for Alzheimer disease.",
keywords = "Aging, Brain metabolism, Dementia, Magnetic resonance spectroscopy, Spectral quantitation",
author = "Gabriela Stoppe and Harald Bruhn and Pouwels, {Petra J.W.} and Wolfgang H{\"a}nicke and Jens Frahm",
year = "2000",
month = "4",
day = "1",
doi = "10.1097/00002093-200004000-00009",
language = "English",
volume = "14",
pages = "112--119",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Alzheimer disease : Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy. / Stoppe, Gabriela; Bruhn, Harald; Pouwels, Petra J.W.; Hänicke, Wolfgang; Frahm, Jens.

In: Alzheimer Disease and Associated Disorders, Vol. 14, No. 2, 01.04.2000, p. 112-119.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Alzheimer disease

T2 - Absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy

AU - Stoppe, Gabriela

AU - Bruhn, Harald

AU - Pouwels, Petra J.W.

AU - Hänicke, Wolfgang

AU - Frahm, Jens

PY - 2000/4/1

Y1 - 2000/4/1

N2 - In vivo magnetic resonance spectroscopy of brain metabolites such as N-acetylaspartate and myo-inositol has been proposed for the diagnosis of Alzheimer disease. Thirty patients with probable Alzheimer disease as well as 22 elderly controls underwent quantitative proton magnetic resonance spectroscopy of parietal gray and white matter with use of a short-echo time localization technique (echo time, 20 ms; repetition times, 6000 and 3000 ms, 2.0 Tesla) providing access to the regional concentrations of N-acetylaspartate, creatine, choline-containing compounds, myo-inositol, glutamate, glutamine, and lactate. No statistically significant alterations of the metabolites were found in patients relative to controls. There were also no differences between patients with early and late onset of the disease and with respect to the presence of APOE-ε4 phenotype. A general trend for slightly decreased levels of N-acetylaspartate and creatine was not observed for their respective concentration ratios. In summary, the spectroscopic findings were in accord with known Alzheimer disease neuropathology, i.e., mild gliosis in white matter as well as mildly enhanced cortical atrophy in comparison to elderly controls. However, cortical atrophy with little or no N-acetylaspartate changes provided no evidence for a major decrease of neuronal density or loss of viable neurons. The data do not support the utility of proton magnetic resonance spectroscopy as an early diagnostic tool for Alzheimer disease.

AB - In vivo magnetic resonance spectroscopy of brain metabolites such as N-acetylaspartate and myo-inositol has been proposed for the diagnosis of Alzheimer disease. Thirty patients with probable Alzheimer disease as well as 22 elderly controls underwent quantitative proton magnetic resonance spectroscopy of parietal gray and white matter with use of a short-echo time localization technique (echo time, 20 ms; repetition times, 6000 and 3000 ms, 2.0 Tesla) providing access to the regional concentrations of N-acetylaspartate, creatine, choline-containing compounds, myo-inositol, glutamate, glutamine, and lactate. No statistically significant alterations of the metabolites were found in patients relative to controls. There were also no differences between patients with early and late onset of the disease and with respect to the presence of APOE-ε4 phenotype. A general trend for slightly decreased levels of N-acetylaspartate and creatine was not observed for their respective concentration ratios. In summary, the spectroscopic findings were in accord with known Alzheimer disease neuropathology, i.e., mild gliosis in white matter as well as mildly enhanced cortical atrophy in comparison to elderly controls. However, cortical atrophy with little or no N-acetylaspartate changes provided no evidence for a major decrease of neuronal density or loss of viable neurons. The data do not support the utility of proton magnetic resonance spectroscopy as an early diagnostic tool for Alzheimer disease.

KW - Aging

KW - Brain metabolism

KW - Dementia

KW - Magnetic resonance spectroscopy

KW - Spectral quantitation

UR - http://www.scopus.com/inward/record.url?scp=0343237713&partnerID=8YFLogxK

U2 - 10.1097/00002093-200004000-00009

DO - 10.1097/00002093-200004000-00009

M3 - Article

VL - 14

SP - 112

EP - 119

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 2

ER -